

**Compliance Oversight Branch
Division of Human Subject Protections
Office for Protection from Research Risks**

OPRR Compliance Activities: Common Findings and Guidance - 11/29/99

INDEX - CLICK TO GO TO ITEM

A. INITIAL AND CONTINUING REVIEW

Common OPRR Findings of Noncompliance

- (1) Failure of IRB to Review HHS Grant Applications
- (2) IRB Lacks Sufficient Information to Make Determinations Required for Approval of Research
- (3) Inadequate IRB Review at Convened Meetings
- (4) Inadequate Continuing Review
- (5) Contingent Approval of Research with Substantive Changes and no Additional Review by the Convened IRB
- (6) Failure to Conduct Continuing Review at Least Once per Year
- (7) IRB Meeting Convened without Quorum (Nonscientist Absent)
- (8) IRB Meeting Convened without Quorum (Lack of a Majority)
- (9) IRB Members with Conflicting Interest Participated in IRB Review of Research

Additional OPRR Guidance

- (10) Loss of Quorum During IRB Meeting
- (11) Requirement for Review by the Convened IRB
- (12) IRB Review in Emergency Situations
- (13) Initial Review Materials
- (14) Primary Reviewer Systems
- (15) Continuing Review for Follow up in Cooperative Protocol Research Program Protocols

B. EXPEDITED REVIEW PROCEDURES

Common OPRR Findings of Noncompliance

- (16) Inappropriate Use of Expedited Review Procedures for Initial or Continuing IRB Review
- (17) Inappropriate Use of Expedited Review Procedures for Review of Protocol Changes
- (18) Failure to Advise IRB Members of Expedited Approvals

Additional OPRR Guidance

- (19) Documentation for Initial and Continuing Expedited Review
- (20) Policies for Expedited Review of Minor Changes

C. REPORTING OF UNANTICIPATED PROBLEMS AND IRB REVIEW OF PROTOCOL CHANGES

Common OPRR Findings of Noncompliance

- (21) Failure to Report Unanticipated Problems to IRB, Institutional Officials, and OPRR
- (22) Failure of IRB to Review Protocol Changes
- (23) Inadequate IRB Review of Protocol Changes

D. APPLICATION OF EXEMPTIONS

Common OPRR Findings of Noncompliance

- (24) Inappropriate Application of Exempt Categories of Research
- (25) Inappropriate Application of Exemption 4

Additional OPRR Guidance

- (26) Procedures for Determining Exemptions
- (27) Applicability of Exemption 2 for Research Involving Children
- (28) Applicability of Exemption 5 for Public Benefit Projects

E. INFORMED CONSENT

Common OPRR Findings of Noncompliance

- (29) Deficient Informed Consent Documents (ICDs) in General
- (30) Inadequate ICD for Specific Research/Lack of Required Elements
- (31) Inadequate ICD for Specific Research/Lack of Additional Elements
- (32) ICD Language too Complex
- (33) Exculpatory Language in ICDs
- (34) Standard Surgical Consent Documents Lack Required Elements of Informed Consent
- (35) Inappropriate Boiler Plate ICDs
- (36) Enrollment Procedures did not Minimize Possibility of Coercion or Undue Influence

Additional OPRR Guidance

- (37) Informed Consent for Research in Emergency Situations.
- (38) Approval and Expiration Dates on Informed Consent Documents
- (39) IRB Review of NIH-Approved Informed Consent Documents for NIH-Supported Multicenter Clinical Trials.
- (40) Description of Notification of HIV Testing Results
- (41) FDA-Regulated Test Articles
- (42) Documentation of Informed Consent for Non-English Speakers

F. IRB MEMBERSHIP, EXPERTISE, STAFF, SUPPORT, AND WORKLOAD

Common OPRR Findings of Noncompliance

- (43) Lack of Diversity of IRB Membership

- (44) Lack of IRB Expertise Regarding Research Involving Children
- (45) Lack of Prisoner/Prisoner Representative for IRB Review of Research Involving Prisoners
- (46) Conflict Resulting from Office of Research Support (Sponsored Programs) Serving as a Voting Member of the IRB
- (47) IRB Chair and Members Lack Sufficient Understanding of HHS Regulations
- (48) Designation of an Additional IRB under an MPA without Prior OPRR Approval
- (49) Inadequate IRB Resources
- (50) Overburdened IRB

Additional OPRR Guidance

- (51) IRB Knowledge of Local Research Context

G. DOCUMENTATION OF IRB ACTIVITIES, FINDINGS, AND PROCEDURES

Common OPRR Findings of Noncompliance

- (52) Inadequate IRB Records
- (53) Inadequate IRB Minutes
- (54) Poorly Maintained IRB Files
- (55) Failure of IRB to Document Consideration of Additional Safeguards for Vulnerable Subjects
- (56) Failure of IRB to Make Required Findings When Reviewing Research Involving Children
- (57) Failure of IRB to Make Required Findings When Reviewing Research Involving Prisoners
- (58) Failure of IRB to Make and Document Required Findings for Waiver of Informed Consent
- (59) Failure to Make Required Findings for IRB Waiver of a Signed Informed Consent Document
- (60) Lack of Appropriate Written IRB Policies and Procedures
- (61) Inadequate Procedures for Oversight of Repository Activities
- (62) Inadequate Procedure for Reporting and Review of Unanticipated Problems

Additional OPRR Guidance

- (63) Recording of Votes in IRB Minutes
- (64) Documentation of Required IRB Findings in IRB Minutes
- (65) Documentation of Risk and Approval Period in IRB Minutes
- (66) Written IRB Guidelines and Procedures

H. MISCELLANEOUS OPRR GUIDANCE

- (67) Protocol Revisions - Incorporation Into Written Protocol
- (68) Operation of Student Human Subject Pools
- (69) Procedures for Control of Investigational Agents
- (70) Applicability of State and Local Laws to HHS-Supported Research
- (71) In Vitro Fertilization Research
- (72) Fetal Tissue Transplantation Research
- (73) Inclusion of Women and Minorities in Research
- (74) Noninstitutional Investigator Agreements in HHS-Supported Multicenter Clinical Trials

A. INITIAL AND CONTINUING REVIEW

Common OPRR Findings of Noncompliance

(1) Failure of IRB to Review HHS Grant Applications. HHS regulations at 45 CFR 46.103(f) require that an institution with an approved assurance shall certify that each *application* for research has been reviewed and approved by the IRB.

(a) OPRR found numerous discrepancies between the title, date, and type of IRB approval reported on the face page of grant applications and the relevant documentation in IRB records.

(b) In reviewing IRB records, and in discussions with IRB members, IRB administrators, and research investigators, OPRR finds that the IRB consistently fails to review the grant application for proposed research.

(2) IRB Lacks Sufficient Information to Make Determinations Required for Approval of Research. OPRR is concerned that when reviewing protocol applications, the IRB often appears to lack sufficient information to make the determinations required for approval of research under HHS regulations at 45 CFR 46.111. For example, the IRB appears to review only minimal information regarding (i) subject recruitment and enrollment procedures; (ii) the equitable selection of subjects; (iii) provisions to protect the privacy of subjects and maintain the confidentiality of data; and (iv) additional safeguards to protect the rights and welfare of subjects who are likely to be vulnerable.

(3) Inadequate IRB Review at Convened Meetings. The minutes of IRB meetings, and our discussions with IRB members and administrators, indicate that little substantive review takes place at convened meetings. Most protocols undergoing [initial/continuing] review are neither individually presented nor discussed at a convened meeting by the IRB as a group. Furthermore, our inspection of available materials yielded scant evidence that IRB approval of research is consistently based on consideration of the determinations required under HHS regulations at 45 CFR 46.111. In specific, the IRB appears not to consider systematically and rigorously such issues as equitable selection of subjects and subject recruitment, privacy and confidentiality protections, and special protections required for vulnerable subjects.

(4) Inadequate Continuing Review. Continuing IRB review of research must be substantive and meaningful. In conducting continuing review, all IRB members should at least receive and review a protocol summary and a status report on the progress of the research, including (i) the number of subjects accrued; (ii) a description of any adverse events or unanticipated problems involving risks to subjects or others and of any withdrawal of subjects from the research or complaints about the research; (iii) a summary of any recent literature, findings obtained thus far, amendments or modifications to the research since the last review, reports on multi-center trials and any other relevant information, especially information about risks associated with the research; and (iv) a copy of the

current informed consent document. Primary reviewer systems may be employed, so long as the full IRB receives the above information. Primary reviewers should also receive a copy of the complete protocol including any modifications previously approved by the IRB (see OPRR Reports 95-01).

OPRR finds that continuing review of research by the IRB regularly failed to satisfy these requirements.

(5) Contingent Approval of Research with Substantive Changes and no Additional Review by the Convened IRB. OPRR finds that the IRB frequently approves research contingent upon substantive modifications or clarifications without requiring additional review by the convened IRB. OPRR recommends the following guidelines in such cases: (i) When the convened IRB requests substantive clarifications, protocol modifications, or informed consent document revisions, IRB approval of the proposed research must be **deferred**, pending subsequent review by the convened IRB of responsive material. (ii) Only when the convened IRB stipulates specific revisions requiring simple concurrence by the investigator may the IRB Chair or designated reviewer subsequently approve the research on behalf of the IRB.

(6) Failure to Conduct Continuing Review at Least Once per Year. HHS regulations at 45 CFR 46.109(e) require that continuing review of research be conducted at intervals appropriate to the degree of risk and not less than once per year. The regulations make no provision for any grace period extending the conduct of the research beyond the expiration date of IRB approval. OPRR found numerous instances in which extensions beyond the expiration date were granted.

If the IRB does not re-approve the research by the specified expiration date, subject accrual should be suspended pending re-approval of the research by the IRB. (Enrollment of new subjects cannot ordinarily occur after the expiration of IRB approval. Continuation of research interventions or interactions in already enrolled subjects should only continue when the IRB finds that it is in the best interests of individual subjects to do so. OPRR and IRBs must address on a case-by-case basis those rare instances where failure to enroll would seriously jeopardize the safety or well-being of an individual **prospective** subject.)

(7) IRB Meeting Convened without Quorum (Nonscientist Absent). HHS regulations at 45 CFR 46.108(b) require that, except when an expedited review procedure is used, research be reviewed at convened meetings at which a majority of the members of the IRB are present, including at least one member whose primary concerns are in a nonscientific area. OPRR finds that the [date] IRB meeting did not include a nonscientist member. Thus, any actions taken at this meeting must be considered invalid. OPRR emphasizes that should the quorum fail during a meeting (e.g., those with conflicts being excused, early departures, loss of a non-scientist), the meeting is terminated from further votes unless the quorum can be restored.

(8) IRB Meeting Convened without Quorum (Lack of a Majority). HHS regulations at 45 CFR 46.108 require that, except when an expedited review procedure is used, the IRB review proposed research at

convened meetings at which a majority of the members of the IRB are present. OPRR found that the IRB failed to meet this requirement for the following IRB meetings: [date], X members present. Thus, any actions taken at these meeting must be considered invalid. OPRR emphasizes that should the quorum fail during a meeting (e.g., those with conflicts being excused, early departures, loss of a nonscientist), the meeting is terminated from further votes unless the quorum can be restored.

(9) IRB Members with Conflicting Interest Participated in IRB Review of Research. HHS regulations at 45 CFR 46.107(e) stipulate that no IRB member may participate in the IRB's initial or continuing review of a project in which the member has a conflicting interest, except to provide information requested by the IRB. OPRR found instances in which IRB members inappropriately participated in the initial and continuing review of protocols for which they had a conflicting interest. OPRR strongly recommends that IRB members absent themselves from the meeting room when the IRB votes on research in which they have a conflicting interest, and such should be noted in the IRB meeting minutes.

Additional OPRR Guidance

(10) Loss of Quorum During IRB Meeting. A quorum for IRB meetings is a majority of the IRB's voting members, including at least one member whose primary interests are in nonscientific areas (see 45 CFR 46.108). Approval of research is by majority vote of those present (i.e., of a valid quorum). Should the quorum fail during a meeting (e.g., those with conflicts being excused, early departures, loss of a non-scientist), the meeting is terminated from further votes unless the quorum can be restored.

(11) Requirement for Review by the Convened IRB. Initial and continuing reviews of research must be conducted by the convened IRB, except where expedited review is appropriate under HHS regulations at 45 CFR 46.110(b)(1) and 63 FR 60364.

(12) IRB Review in Emergency Situations. HHS regulations do not permit research activities to be started, even in an emergency, without prior IRB review and approval (see 45 CFR 46.103(b), 46.116(f) and OPRR Reports 91-01). When emergency medical care is initiated without prior IRB review and approval, the patient may not be considered a research subject. Such emergency care may not be claimed as research, nor may any data regarding such care be included in any report of a research activity. When emergency care involves investigational drugs, devices, or biologics, U.S. Food and Drug Administration (FDA) requirements must be satisfied

(13) Initial Review Materials. In conducting the initial review of proposed research, IRBs must obtain information in sufficient detail to make the determinations required under HHS regulations at 45 CFR 46.111. Materials should include the full protocol, a proposed informed consent document, any relevant grant applications, the investigator's brochure (if one exists), and any advertising intended to be seen or heard by potential subjects. Unless a primary reviewer system is used, all members should receive a copy of the complete documentation. These materials should be received by members sufficiently in advance of the meeting date to allow review of this material.

(14) Primary Reviewer Systems. If the IRB uses a primary reviewer system, the primary reviewer(s) should do an in-depth review of all pertinent documentation (see (4) above). All other IRB members should at least receive and review a protocol summary (of sufficient detail to make the determinations required under HHS regulations at 45 CFR 46.111), the proposed informed consent document, and any advertising material. In addition, the complete documentation should be available to all members for review.

(15) Continuing Review for Follow up in Cooperative Protocol Research Program Protocols. Continuing IRB review is required as long as individually identifiable follow-up data are collected on subjects enrolled in HHS-supported Cooperative Protocol Research Program (CPRP) protocols. This remains the case even after a protocol has been closed at all sites and protocol-related treatment has been completed for all subjects.

B. EXPEDITED REVIEW PROCEDURES

Common OPRR Findings of Noncompliance

(16) Inappropriate Use of Expedited Review Procedures for Initial or Continuing IRB Review. HHS regulations at 45 CFR 46.110(b)(1) limit the use of expedited review procedures to specific research categories published in the Federal Register at 63 FR 60364. OPRR finds that:

(a) The IRB inappropriately confounds the concepts of minimal risk and expedited review.

(b) Use of expedited review by the IRB has not been restricted to these categories. OPRR recommends that documentation for initial and continuing reviews that are conducted utilizing expedited review procedures include citation of the specific permissible categories (see 63 FR 60364) justifying the expedited review.

(17) Inappropriate Use of Expedited Review Procedures for Review of Protocol Changes. HHS regulations at 45 CFR 46.110(b)(2) permit use of expedited procedures for review of minor changes to previously approved research. OPRR finds that the IRB has employed expedited procedures to review changes that exceed this limitation.

(18) Failure to Advise IRB Members of Expedited Approvals. OPRR finds that IRB members were not advised of (i) initial or continuing review approvals of research protocols, or (ii) approvals of minor changes in research protocols as required by HHS regulations at 45 CFR 46.110(c).

Additional OPRR Guidance

(19) Documentation for Initial and Continuing Expedited Review. OPRR recommends that documentation for initial and continuing reviews conducted utilizing expedited review procedures include the specific permissible categories (see 63 FR 60364) justifying the expedited review.

(20) Policies for Expedited Review of Minor Changes. OPRR recommends that institutions adopt policies describing the types of minor changes in previously approved research which can be approved by expedited review in accordance with HHS regulations at 45 CFR 46.110(b)(2).

C. REPORTING OF UNANTICIPATED PROBLEMS AND IRB REVIEW OF PROTOCOL CHANGES

Common OPRR Findings of Noncompliance

(21) Failure to Report Unanticipated Problems to IRB, Institutional Officials, and OPRR. OPRR finds that the following unanticipated problems involving risks to subjects or others were not reported to [appropriate institutional officials/the IRB/OPRR/the head of the sponsoring Federal department or agency] as required by HHS regulations at 45 CFR 46.103(b)(5):

(22) Failure of IRB to Review Protocol Changes. HHS regulations at 45 CFR 46.103(b)(4)(iii) require that the IRB review and approve all proposed changes in a research activity, during the period for which IRB approval has already been given, prior to initiation of such changes, except when necessary to eliminate apparent immediate hazards to the subjects. OPRR finds no documentation that the IRB reviewed and approved the following protocol changes prior to their initiation:

(23) Inadequate IRB Review of Protocol Changes. OPRR is concerned about the adequacy of the IRB's procedure for reviewing protocol modifications. In some cases, the IRB Chair or designated IRB reviewer approved such modifications in the absence of a complete description of the proposed changes.

D. APPLICATION OF EXEMPTIONS

Common OPRR Findings of Noncompliance

(24) Inappropriate Application of Exempt Categories of Research. HHS regulations at 45 CFR 46.101(b) delineate six specific categories of exempt activities. OPRR finds that the institution has applied exempt status to research activities that exceed these categories. OPRR recommends that documentation for all exemptions include citation of the specific category justifying the exemption.

(25) Inappropriate Application of Exemption 4. HHS regulations at 45 CFR 46.101(b)(4) exempt activities involving existing data, documents, records, or specimens. OPRR notes that such materials must already exist at the time the research is proposed. OPRR finds instances where this exemption was applied to activities involving prospective collection of such materials.

Additional OPRR Guidance

(26) Procedures for Determining Exemptions. OPRR recommends that institutions adopt clear procedures under which the IRB (or some authority other than the investigator) determines whether proposed research is exempt from the human subjects regulations [see 45 CFR 46.101(b)]. Documentation should include the specific category justifying the exemption.

(27) Applicability of Exemption 2 for Research Involving Children. OPRR emphasizes that the exemption at 45 CFR 46.101(b)(2) for research involving survey or interview procedures or observations of public behavior does not apply to research covered by 45 CFR Part 46, Subpart D (Additional DHHS Protections for Children Involved as Subjects in Research), except for research involving observation of public behavior when the investigators do not participate in the activities being observed.

(28) Applicability of Exemption 5 for Public Benefit Projects. The following criteria (see 48 FR 9266-9270) must be satisfied to invoke the exemption for research and demonstration projects examining "public benefit or service programs" as specified under HHS regulations at 45 CFR 46.101(b)(5): (i) The program under study must deliver a public benefit (e.g., financial or medical benefits as provided under the Social Security Act) or service (e.g., social, supportive, or nutrition services as provided under the Older Americans Act). (2) The research or demonstration project must be conducted pursuant to specific federal statutory authority. (3) There must be no statutory requirement that the project be reviewed by an Institutional Review Board (IRB). (4) The project must not involve significant physical invasions or intrusions upon the privacy of participants. NOTE: This exemption is for Federally-supported projects and is most appropriately invoked with authorization or concurrence by the funding agency. Institutions retain the option under their Assurances not to claim the exemptions provided in the regulations, choosing instead to require IRB review of all research involving human intervention/interaction or identifiable private information.

E. INFORMED CONSENT

Common OPRR Findings of Noncompliance

(29) Deficient Informed Consent Documents (ICDs) in General. HHS regulations at 45 CFR 46.116(a) delineate specific elements required for informed consent. OPRR found instances where (i) required elements were omitted; and (ii) there were discrepancies between the protocol application and the informed consent documents regarding the purpose, risks, and benefits of the research.

(30) Inadequate ICD for Specific Research/Lack of Required Elements. OPRR finds that the informed consent documents reviewed and approved by the IRB between [date X] and [date Y] for [study Z] failed to include the following elements required by HHS regulations at 45 CFR 46.116 (a):

(a) Section 46.116(a)(1): (i) A clear statement that the study involves research; (ii) an explanation of the purposes of the research (i.e., [summary of purpose]); (iii) the expected duration of the subject's participation; and (iv) a complete description of the procedures to be followed, and identification of any procedures which are experimental (i.e., [procedures not described]).

(b) Section 46.116(a)(2): An adequate description of the reasonably foreseeable risks and discomforts (i.e., [risks and discomforts not described]).

(c) Section 46.116(a)(3): An adequate description of any benefits to the subject or others that may *reasonably* be expected from the research.

(d) Section 46.116(a)(4): A description of appropriate alternative procedures or courses of treatment that might be advantageous to the subject (e.g., [alternatives which should be described]).

(e) Section 46.116(a)(5): A description of how confidentiality and privacy will be maintained.

(f) Section 46.116(a)(6): An explanation as to whether any compensation and an explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained.

(g) Section 46.116(a)(7): An explanation of whom to contact for answers to questions about research subjects' rights (should include someone other than the investigator), and whom to contact in the event of a research-related injury to the subject.

(h) Section 46.116(a)(8): A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled.

(31) Inadequate ICD for Specific Research/Lack of Additional Elements. OPRR finds that it would have been appropriate for the informed consent documents to include the following additional elements in accordance with HHS regulations at 45 CFR 46.116(b):

(a) Section 46.116(b)(2): Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent.

(b) Section 46.116(b)(4): The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject.

(c) Section 46.116(b)(5): A statement that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject.

(32) ICD Language too Complex. HHS regulations at 45 CFR 46.116 require that the information provided in the informed consent documents be in language understandable to the subject. OPRR is concerned that the informed consent document approved by the IRB for this study appeared to include complex language that would not be understandable to all subjects.

(33) Exculpatory Language in ICDs. HHS regulations at 45 CFR 46.116 prohibit any exculpatory language in informed consent through which the subject is made to waive, or appear to waive, any of the subject's legal rights. OPRR finds the following language in the IRB-approved informed consent documents to be exculpatory:

(34) Standard Surgical Consent Documents Lack Required Elements of Informed Consent. OPRR notes that standard surgical consent documents rarely include all the elements required under HHS regulations at 45 CFR 46.116. Reliance on such documents for research generally requires formal waiver of consent requirements in accordance with Section 46.116(d), which requires that the IRB find and document four specific conditions. OPRR finds no documentation of such waiver in protocols for which surgical consent was accepted in lieu of an IRB-approved research consent document.

(35) Inappropriate Boiler Plate ICDs. OPRR is concerned that the boilerplate informed consent document is difficult to understand and contains information that may be irrelevant for certain research.

(36) Enrollment Procedures did not Minimize Possibility of Coercion or Undue Influence. OPRR finds that the procedures for enrolling subjects failed to minimize the possibility of coercion or undue influence as required by HHS regulations at 45 CFR 46.116.

Additional OPRR Guidance

(37) Informed Consent for Research in Emergency Situations. Nothing in the HHS regulations at 45 CFR Part 46 is intended to limit the authority of a physician to provide emergency medical care, to the extent the physician is permitted to do so under applicable Federal, State, or local law. However, when emergency medical care is initiated without the physician obtaining and documenting the legally effective informed consent of the patient or the patient's legally authorized representative for participation in research (unless the IRB has appropriately waived such requirements), the patient may not be considered a research subject. Such emergency care may not be claimed as research, nor may any data regarding such care be included in any report of a research activity. When emergency care involves investigational drugs, devices, or biologics, U.S. Food and Drug Administration requirements must be satisfied

(38) Approval and Expiration Dates on Informed Consent Documents. OPRR recommends that IRBs affix the approval and expiration dates to all approved informed consent documents and stipulate that copies of these dated documents must be used in obtaining consent. This procedure helps ensure that only the current, IRB-approved informed consent documents are presented to subjects and serves as a reminder to the investigators of the need for continuing review.

The approval date should be the most recent of the following: (i) date the protocol and informed consent document were initially reviewed and approved by the IRB; (ii) date of the most recent IRB continuing review and approval of the protocol and informed consent document; or (iii) date that the IRB approved the most recent modification to the informed consent document. In all three circumstances, the approval date which appears on the consent document is the date of approval of the most recent version of the consent document. The expiration date should correspond to the end of the current IRB approval period.

(39) IRB Review of NIH-Approved Informed Consent Documents for NIH-Supported Multicenter Clinical Trials. OPRR requires that each local IRB receive and review a copy of the NIH-approved sample informed consent document and the full NIH-approved protocol as a condition for review and approval of the local informed consent document. Any deletion or substantive modification of information concerning risks or alternative procedures contained in the sample informed consent document must be justified in writing by the investigator, approved by the IRB, and reflected in the IRB minutes (see OPRR Reports 93-01).

(40) Description of Notification of HIV Testing Results. PHS policy (applicable to all PHS-supported intramural and extramural, foreign and domestic research and health activities) requires that where HIV testing is conducted or supported by PHS, individuals whose test results are associated with personal identifiers must be informed of their own test results and provided the opportunity to receive appropriate counseling unless the situation calls for an exception under the special circumstances set forth in the Policy (See OPRR Reports 6/10/88). This procedure should be described in the informed consent document.

(41) FDA-Regulated Test Articles. For all research involving test articles regulated by the U.S. Food and Drug Administration (FDA), informed consent documents should include a statement that the purpose of the study includes evaluation of both the safety and the effectiveness of the test article.

(42) Documentation of Informed Consent for Non-English Speakers. The regulations require that informed consent information be presented "in language understandable to the subject" and, in most situations, that informed consent be documented in writing (see 45 CFR 46.116 and 46.117). Where informed consent is documented in accordance with HHS regulations at 45 CFR 46.117(b)(1), the written informed consent document should embody, in language understandable to the subject, all the elements necessary for legally effective informed consent. Subjects who do not speak English should be presented with an informed consent document written in a language understandable to them. OPRR strongly encourages the use of this procedure whenever possible. Alternatively, HHS regulations at 45 CFR 46.117(b)(2) permit oral presentation of informed consent information in conjunction with a short form written informed consent document (stating that the elements of consent have been presented orally) and a written summary of what is presented orally. A witness to the oral presentation is required, and the subject must be given copies of the short form document and the summary. When this procedure is used with subjects who do not speak English, (i) the oral presentation and the short form written informed consent document should be in a language understandable to the subject; (ii) the IRB-approved English language informed consent document may serve as the summary; and (iii) the witness should be fluent in both English and the language of the subject.

F. IRB MEMBERSHIP, EXPERTISE, STAFF, SUPPORT, AND WORKLOAD

Common OPRR Findings of Noncompliance

(43) Lack of Diversity of IRB Membership. OPRR is concerned that the current IRB membership appears to lack the diversity, including consideration of race, gender, and cultural backgrounds and sensitivity to such issues as community attitudes, to promote respect for its advice and counsel in safeguarding the rights and welfare of human subjects, as required under HHS regulations at 45 CFR 46.107(a).

(44) Lack of IRB Expertise Regarding Research Involving Children. HHS regulations at 45 CFR 46.107(a) require that an IRB which regularly reviews research involving a vulnerable category of subjects consider inclusion of one or more individuals who are knowledgeable about and experienced in working with these subjects. OPRR finds that the volume of research involving children reviewed by the IRB warrants inclusion of such an individual.

(45) Lack of Prisoner/Prisoner Representative for IRB Review of Research Involving Prisoners. HHS regulations at 45 CFR 46.304 require modification of IRB membership for review of research involving prisoners. In specific, at least one member of the IRB shall be a prisoner, or a prisoner representative

with appropriate background and experience to serve in that capacity. OPRR finds that the IRB failed to meet this requirement when reviewing research projects involving prisoners.

(46) Conflict Resulting from Office of Research Support (Sponsored Programs) Serving as a Voting Member of the IRB. HHS regulations at 45 CFR 46.107(e) stipulate that no IRB member may participate in the initial or continuing review of any project in which the member has a conflicting interest. OPRR finds that the Director of the Office of Research Support (ORS) [**OR** Office of Grants and Contracts] serves as a voting member of the IRB. OPRR has determined that individuals from ORS whose duties create a real or apparent conflicting interest should not serve as *voting* IRB members.

(47) IRB Chair and Members Lack Sufficient Understanding of HHS Regulations. OPRR is concerned that the IRB Chair and members appear to lack a detailed understanding of the specific requirements of the HHS regulations for the protection of human subjects. As a result, IRB determinations have sometimes deviated from these requirements.

(48) Designation of an Additional IRB under an MPA without Prior OPRR Approval. The institution's MPA presently designates a single IRB. Designation of additional IRBs under the MPA requires prior notification of and approval by OPRR. OPRR finds that the institution has established a second IRB without such approval.

(49) Inadequate IRB Resources. HHS regulations at 45 CFR 46.103(b)(2) require that institutions provide meeting space and sufficient staff to support the IRB's review and recordkeeping duties. OPRR is concerned that (i) the IRB administrative staff lacks space and privacy sufficient to conduct sensitive IRB duties; and (ii) the level of staff support provided to the IRB appears to be insufficient. It is OPRR's experience that the volume of human subjects research conducted by the institution warrants [a full-time IRB administrator at the professional level/additional IRB staff members].

(50) Overburdened IRB. OPRR is concerned that items (X)-(Y) above may be indicative of an IRB overburdened by the large volume of research for which it has oversight responsibility. It is OPRR's experience that such a large volume of human subjects research warrants more than one fully functional IRB.

Additional OPRR Guidance

(51) IRB Knowledge of Local Research Context. HHS regulations at 45 CFR 46.103(d) require that the adequacy of Institutional Review Boards (IRBs) be evaluated in light of the anticipated scope of the institution's research activities, the types of subject populations likely to be involved, . . . and the size and complexity of the institution. The regulations further require at 45 CFR 46.107(a) that IRBs be (i) sufficiently qualified through . . . the diversity of the members, including consideration of race, gender, and cultural backgrounds and sensitivity to such issues as community attitudes, to promote respect for its advice and counsel; and (ii) able to ascertain the acceptability of proposed research in terms of

institutional commitments and regulations, applicable law, and standards of professional conduct and practice. Institutions have a profound responsibility to ensure that all IRBs designated under an OPRR-approved Assurance possess sufficient knowledge of the local research context to satisfy these requirements.

For detailed guidance on appropriate mechanisms for ensuring that the IRB has adequate knowledge of the local research context, please see:

<http://grants.nih.gov/grants/oprr/humansubjects/guidance/local.htm>

G. DOCUMENTATION OF IRB ACTIVITIES, FINDINGS, AND PROCEDURES

Common OPRR Findings of Noncompliance

(52) Inadequate IRB Records. OPRR finds that IRB protocol records fail to include all the information stipulated at 45 CFR 46.115(a)(1),(3),(4), and (7).

(53) Inadequate IRB Minutes. HHS regulations at 45 CFR 46.115(a)(2) require that minutes of IRB meetings be in sufficient detail to show attendance at the meetings; actions taken by the IRB; the vote on these actions including the number of members voting for, against, and abstaining; the basis for requiring changes in or disapproving research; and a written summary of the discussion of controverted issues and their resolution. OPRR finds that IRB minutes often failed to meet these requirements. Furthermore, OPRR notes that IRB actions were not documented separately for each individual protocol.

(54) Poorly Maintained IRB Files. In numerous instances among the IRB files examined by OPRR, it was difficult to reconstruct a complete history of all IRB actions related to review and approval of the protocol. In some instances, OPRR could not determine what the IRB actually approved.

(55) Failure of IRB to Document Consideration of Additional Safeguards for Vulnerable Subjects. HHS regulations at 45 CFR 46.111(b) require the IRB to ensure that additional safeguards have been included in research to protect the rights and welfare of vulnerable subjects. OPRR finds that IRB records failed to demonstrate consistently the consideration of such safeguards.

(56) Failure of IRB to Make Required Findings When Reviewing Research Involving Children. HHS regulations at 45 CFR 46.404-407 require specific findings on the part of the IRB for approval of research involving children. OPRR's discussions with IRB members and its review of IRB documents reveals no evidence that the IRB consistently makes the required findings when reviewing research involving children. [See item (64) below for guidance.]

(57) Failure of IRB to Make Required Findings When Reviewing Research Involving Prisoners. HHS regulations at 45 CFR 46.305-306 require specific findings on the part of the IRB for approval of research involving prisoners. OPRR's discussions with IRB members and its review of IRB documents reveals no evidence that the IRB makes the required findings when reviewing such research. [See item (64) below for guidance.]

(58) Failure of IRB to Make and Document Required Findings for Waiver of Informed Consent. HHS regulations at 45 CFR 46.116(d) require that the IRB find and document four specific criteria when approving waiver or alteration of some or all of the required elements of informed consent. OPRR's discussions with IRB members and its review of IRB documents reveals no evidence that the IRB consistently satisfies these requirements. [See item (64) below for guidance.]

(59) Failure to Make Required Findings for IRB Waiver of a Signed Informed Consent Document. HHS regulations at 45 CFR 46.117(c) require specific findings on the part of the IRB for waiver of the usual requirements for the investigator to obtain a signed consent form from all subjects. OPRR's discussions with IRB members and its review of IRB documents reveals no evidence that the IRB makes the required findings when approving such waivers.

(60) Lack of Appropriate Written IRB Policies and Procedures. OPRR finds that the institution does not have written IRB policies and procedures that adequately describe the following activities required by HHS regulations at 45 CFR 46.103(b)(4) and (5):

(a) The procedures which the IRB will follow (i) for conducting its initial and continuing review of research and for reporting its findings and actions to the investigator and the institution; (ii) for determining which projects require review more often than annually and which projects need verification from sources other than the investigators that no material changes have occurred since previous IRB review; and (iii) for ensuring prompt reporting to the IRB of proposed changes in a research activity, and for ensuring that such changes in approved research, during the period for which IRB approval has already been given, may not be initiated without IRB review and approval except when necessary to eliminate apparent immediate hazards to the subject.

(b) The procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and Department or Agency head of (i) any unanticipated problems involving risks to subjects or others or any serious or continuing noncompliance with 45 CFR Part 46 or the requirements or determinations of the IRB; and (ii) any suspension or termination of IRB approval.

(61) Inadequate Procedures for Oversight of Repository Activities. OPRR notes that the institution is engaged in several tissue banking or repository activities. These activities require the IRB to make determinations concerning (i) the regulatory status and appropriate use of stored biologic samples, and (ii) the informed consent process for research using such samples. OPRR is concerned that the IRB has not developed policies and procedures for oversight of repository activities that ensure compliance

with HHS regulations at 45 CFR Part 46 (see guidance at <http://grants.nih.gov/grants/oprr/humansubjects/guidance/reposit.htm>).

(62) Inadequate Procedure for Reporting and Review of Unanticipated Problems. OPRR is concerned about the adequacy of the IRB's present procedures for ensuring prompt reporting, review, and evaluation of unanticipated problems involving risks to subjects or others.

Additional OPRR Guidance

(63) Recording of Votes in IRB Minutes. HHS regulations at 45 CFR 46.115(a)(2) require that the minutes of IRB meetings document the vote on all IRB actions including the number of members voting for, against, and abstaining. In order to document the continued existence of a quorum, OPRR strongly recommends that votes be recorded in the minutes using the following format: Total = 15; Vote: For-14, Opposed-0, Abstained-1 (NAME).

(64) Documentation of Required IRB Findings in IRB Minutes. Where HHS regulations require specific findings on the part of the IRB, such as (i) approving a procedure which alters or waives the requirements for informed consent [see 45 CFR 46.116(d)], (ii) approving a procedure which waives the requirement for obtaining a signed consent form [see 45 CFR 46.117(c)], (iii) approving research involving prisoners (see 45 CFR 46.305-306), or (iv) approving research involving children (see 45 CFR 46.404-407), OPRR strongly recommends that these findings be fully documented in the IRB minutes, including protocol-specific information justifying each IRB finding.

(65) Documentation of Risk and Approval Period in IRB Minutes. IRBs must determine which protocols require continuing review more often than annually, as appropriate to the degree of risk [see 45 CFR 46.103(b)(4) and 46.109(e)]. OPRR recommends that the minutes of IRB meetings clearly reflect these determinations regarding risk and approval period (review interval).

(66) Written IRB Guidelines and Procedures. OPRR strongly recommends that institutions develop and distribute a handbook of IRB guidelines for research investigators. The handbook should include detailed information concerning (i) federal and institutional requirements for the protection of human research subjects; (ii) the IRB's role and responsibilities; (iii) the requirements and procedures for initial and continuing IRB review and approval of research; (iv) the rationale and procedures for proposing that the research may meet the criteria for expedited review; (v) the requirements and procedures for verifying that research is exempt from IRB review; (vi) the responsibilities of investigators during the review and conduct of research; (vii) requirements and procedures for notifying the IRB of unanticipated problems or events involving risks to the subjects, as well as any other expected or unexpected adverse events; (viii) an explanation of the distinction between FDA requirements for emergency use of test articles versus HHS regulations for the conduct of human subjects research; (ix) relevant examples and user-friendly forms for providing information to the IRB; and (x) a copy of the institution's MPA, the HHS humans subjects regulations (45 CFR Part 46), and *The Belmont Report*. Where appropriate,

OPRR also recommends that IRBs develop written operating procedures to supplement its guidelines for investigators.

H. MISCELLANEOUS OPRR GUIDANCE

(67) Protocol Revisions - Incorporation Into Written Protocol. OPRR recommends that each revision to a research protocol be incorporated into the written protocol. This practice ensures that there is only one complete protocol with the revision dates noted on each revised page and the first page of the protocol itself. This procedure is consistent with the procedure used for revised and approved informed consent documents which then supersede the previous one.

(68) Operation of Student Human Subject Pools. OPRR recommends that IRBs exercise oversight over the operation of student "human subject pools." Subject pool procedures must be in accordance with HHS regulations and must ensure (i) that consent for participation is sought only under circumstances which minimize the possibility of coercion or undue influence, and (ii) that genuinely equivalent alternatives to participation are available.

(69) Procedures for Control of Investigational Agents. OPRR recommends that institutions develop procedures to ensure appropriate control of investigational agents through (a) control of such agents through a central pharmacy; (b) written notification to the pharmacy by the IRB when protocols are approved, suspended, or terminated; and (c) verification of informed consent by the pharmacy before dispensing to subjects.

(70) Applicability of State and Local Laws to HHS-Supported Research. The HHS regulations do not affect any applicable State or local laws or regulations which provide additional protections for human subjects [see 45 CFR 46.101(f)].

(71) In Vitro Fertilization Research. Research proposals involving in vitro fertilization of human ova may now be submitted to and funded by HHS components without prior review and advice of a national ethical advisory board (see OPRR Reports 94-03).

(72) Fetal Tissue Transplantation Research. Public Law 103-43 establishes specific conditions for conduct of HHS-supported research on transplantation of human fetal tissue for therapeutic purposes. Among these conditions are special requirements for informed consent of the donor, informed consent of the researcher and donee, availability of statements for audit, and reporting to Congress (see OPRR Reports 94-02).

(73) Inclusion of Women and Minorities in Research. Institutions have an responsibility to create an environment in which equitable selection of research participants is fostered. IRBs should specify that NIH-supported investigators provide details of the proposed involvement of humans in the research,

including the characteristics of the subject population, anticipated numbers, age ranges, and health statuses. The proposed research should specify the gender and racial/ethnic composition of the subject population, as well as criteria for inclusion or exclusion of any subpopulation. If ethnic, racial, and gender estimates and continuing review numbers are not included in the background data for a protocol, the investigators must provide a clear rationale for exclusion of this information (see OPRR Reports 94-01).

(74) Noninstitutional Investigator Agreements in HHS-Supported Multicenter Clinical Trials.

Noninstitutional Investigator Agreements (NIAs) are required from investigators who participate in OPRR-recognized Cooperative Protocol Research Programs (CPRPs) when such investigators act in their own name independent of any hospital, clinic, or other institution. An NIA is not required for referral physicians or other physicians to whom research subjects are returned by an investigator who maintains responsibility for management of subjects. When a patient/participant accrued by a registered clinical trial investigator (as defined in Section 14.1 of the NCI Investigators Handbook) is referred back to a local physician for protocol-related care or follow up, the local physician would not be required to have an NIA so long as (a) the registered clinical trial investigator retains responsibility for oversight of protocol-related activities; (b) the local physician may not accrue subjects or obtain informed consent for research participation; (c) the local physician may only provide data to the registered clinical trial investigator in accord with the terms of the informed consent document; and (d) the informed consent document should state that such data are to be provided by the local physician as directed by the clinical trial investigator.